References
- Kantor ED, Rehm CD, Haas JS, et al. Trends in prescription drug use among adults in the United States from 1999–2012. JAMA. 2015;314:1818–1830.
- Hodges NL, Spiller HA, Casavant MJ, et al. Non-health care facility medication errors resulting in serious medical outcomes. Clin Toxicol. 2018;56:43–50.
- Olson KR, Erdman AR, Woolf AD. Calcium channel blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2005;43:797–822.
- Wax PM, Erdman AR, Chyka PA, et al. beta-Blocker ingestion: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol. 2005;43:131–146.
- Naccarelli GV, Lukas MA. Carvedilol’s antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. Clin Cardiol. 2005;28:165–173.
- Fava M, Rush AJ, Thase ME, et al. 15 years of clinical experience with bupropion HCl: from bupropion to bupropion SR to bupropion XL. Primary Care Companion J Clin Psychiatry. 2005;7:106–113.
- Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59:366–373.
- Dwoskin LP, Rauhut AS, King-Pospisil KA, et al. Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent. CNS Drug Rev. 2006;12:178–207.
- Starr P, Klein-Scwartz W, Spiller H, et al. Incidence and onset of delayed seizures after overdoses of extended-release bupropion. Am J Emerg Med. 2009;27:911–915.
- Boostani R, Derakhshan S. Tramadol induced seizure: a 3-year study. Caspian J Intern Med. 2012;3:484–487.
- Dayer P, Collart L, Desmeules J. The pharmacology of tramadol. Drugs. 1994;47:3–7.